Soligenix Inc. (SNGX) shares sank 25.78% to trade at $0.95 in after-market on Friday, May 7, 2021. Earlier, SNGX’s stock price remained unchanged to close Friday’s session at $1.28. SNGX shares have declined 20.50% over the last 12 months, and they have moved down 11.11% in the past week. Over the past three months, the stock has lost 22.42%, while over the past six months, it has shed 20.50%.
Let’s see what’s going on with the SNGX?
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
HyBrytePhase 3 data presentation
On May 4, 2021, Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine and the Lead Principal Investigator for the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study presented confirmatory data at the Society for Investigative Dermatology (SID) Virtual Meeting, held May 3-8, 2021.
Read More
The data confirmed the ability of HyBryte™ (SGX301) to treat both patch and plaque disease, including generating complete disease responses, with fewer side effects. The Phase 3 FLASH trial enrolled a total of 169 patients.
HyBryte™ (SGX301) is Soligenix’s novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation.
Earlier, Ellen Kim presented the data related to the efficacy and safety of HyBryte™ (SGX301) in the treatment of cutaneous T-cell lymphoma (CTCL) at the American Academy of Dermatology (AAD) Association Virtual Meeting Experience, which held on April 23-25, 2021.
Potency demonstration of CiVax™ (COVID-19 vaccine)
On April 28, 2021, Soligenix, Inc. reported that the company has delivered a presentation demonstrating the potency of the CiVax™ (COVID-19 vaccine) development program in mice and non-human primates (NHPs), at the Annual Conference on Vaccinology Research (ACVR) which held on April 26-27, 2021.
Recent financial results
On March 30, 2021, Soligenix, Inc reported its financial results for the year ended December 31, 2020.
FY2020 financial highlights
- Soligenix’searned revenues for $2.4 million for the year ended December 31, 2020, compared to $4.6 million for the year ended December 31, 2019.
- It suffered a basic net loss of $17.7 million, or $0.64per share, for the FY2020 compared to $9.4 million, or $0.48 per share in FY2019.
- In FY2020, the company spent $10.1 million in research and development expenses compared to $8.1 million in FY 2019.
- General and administrative expenses were $4.0 million in the reported year as compared to $3.5 million for the year ended December 31,
- The company had approximately $18.7 million of cash on December 31, 2020.
Conclusion
There was no recent development behind its after-market loss on Friday. SNGX has many products in the pipeline and its price can go up upon approval of those products.
